|
1
|
Dong J, Wei H, Han M, Guan Y, Wu Y and Li
H: Collagen type III glomerulopathy: A case report and review of 20
cases. Exp Ther Med. 10:1445–1449. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Anitha A, Vankalakunti M, Siddini V, Babu
K, Bonu R and Ballal S: Type III collagen disorders: A case report
and review of literature. Indian J Pathol Microbiol. 59:75–77.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fogo AB, Lusco MA, Najafian B and Alpers
CE: AJKD atlas of renal pathology: Type III collagen
glomerulopathy. Am J Kidney Dis. 69:e25–e26. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Patro KC, Jha R, Sahay M and Swarnalatha
G: Collagenofibrotic glomerulopathy-case report with review of
literature. Indian J Nephrol. 21:52–55. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rørtveit R, Eggertsdóttir AV, Thomassen R,
Lingaas F and Jansen JH: A clinical study of canine collagen type
III glomerulopathy. BMC Vet Res. 9(218)2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu H, Chen J, Zhang Y, Wang S and Zou W:
Clinicopathologic features of collagen III glomerulopathy. Zhonghua
Bing Li Xue Za Zhi. 43:732–735. 2014.(In Chinese). PubMed/NCBI
|
|
7
|
Malik S, Suchal K, Gamad N, Dinda AK, Arya
DS and Bhatia J: Telmisartan ameliorates cisplatin-induced
nephrotoxicity by inhibiting MAPK mediated inflammation and
apoptosis. Eur J Pharmacol. 748:54–60. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kwon YJ, Suh GH, Kang SS and Kim HJ:
Successful management of proteinuria and systemic hypertension in a
dog with renal cell carcinoma with surgery, telmisartan, and
amlodipine. Can Vet J. 59:759–762. 2018.PubMed/NCBI
|
|
9
|
Liang W, Chen C, Shi J, Ren Z, Hu F, van
Goor H, Singhal PC and Ding G: Disparate effects of eplerenone,
amlodipine and telmisartan on podocyte injury in
aldosterone-infused rats. Nephrol Dial Transplant. 26:789–799.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mikami D, Kimura H, Kamiyama K, Torii K,
Kasuno K, Takahashi N, Yoshida H and Iwano M: Telmisartan activates
endogenous peroxisome proliferator-activated receptor-δ and may
have anti-fibrotic effects in human mesangial cells. Hypertens Res.
37:422–431. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang ZK, Liu ZY and Yu HB: Protective
effect of telmisartan on rats with renal failure and its mechanism.
Asian Pac J Trop Med. 8:498–501. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kunitomi M, Wada J, Miyatake N, Hayashi Y,
Ota K and Makino H: Ultrastructure of mesangial type III collagen
deposition in a patient with IgA nephropathy. Am J Kidney Dis.
32:146–152. 1998.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ng YF, Chow CY, Yang WS, Lye WC and Loh
HL: Collagenofibrotic glomerulopathy-report of a rare renal disease
with serial biopsies. Malays J Pathol. 42:131–135. 2020.PubMed/NCBI
|
|
14
|
Matthai SM, Mohapatra A, Duhli N, David VG
and Varughese S: Collagenofibrotic glomerulopathy-A rare disease
diagnosed with the aid of transmission electron microscopy. Indian
J Pathol Microbiol. 63:S47–S49. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen X, Wang H, Xu W and Zhu J: Collagen
type III glomerulopathy: Case report and review of the literature.
Clin Nephrol. 87:39–46. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Kurien AA, Larsen CP and Cossey LN:
Collagenofibrotic glomerulopathy. Clin Kidney J. 8:543–547.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pizzo HP, Haas M and Puliyanda D: Collagen
type III glomerulopathy. Kidney Int. 93(1490)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alsaad KO, Edrees B, Rahim KA, Alanazi A,
Ahmad M and Aloudah N: Collagenofibrotic (collagen type III)
glomerulopathy in association with diabetic nephropathy. Saudi J
Kidney Dis Transpl. 28:898–905. 2017.PubMed/NCBI
|
|
19
|
Cohen AH: Collagen type III
glomerulopathies. Adv Chronic Kidney Dis. 19:101–106.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li L, Zou WZ, Wang SX, Wang SL, Wang W,
Han ZH, Du J and Bo L: Collagen type III glomerulopathy: A
morphologic study. Zhonghua Bing Li Xue Za Zhi. 34:385–388.
2005.(In Chinese). PubMed/NCBI
|
|
21
|
Bao H, Chen H, Zhu X, Xu F, Zhu M, Zhang
M, He Q, Zeng C and Liu Z: Clinical and morphological features of
collagen type III glomerulopathy: A report of nine cases from a
single institution. Histopathology. 67:568–576. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vogt BA, Wyatt RJ, Burke BA, Simonton SC
and Kashtan CE: Inherited factor H deficiency and collagen type III
glomerulopathy. Pediatr Nephrol. 9:11–15. 1995.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen N, Pan X, Xu Y, Wang Z, Shi H, Yan F
and Dong X: Two brothers in one Chinese family with collagen type
III glomerulopathy. Am J Kidney Dis. 50:1037–1042. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nimmagadda S, Mukku K, Devaraju SR and
Uppin MS: Unusual cause of glomerular deposition disease:
Collagenofibrotic glomerulopathy. Indian J Nephrol. 27:62–65.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang K, Hu J, Luo T, Wang Y, Yang S, Qing
H, Cheng Q and Li Q: Effects of angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers on all-cause
mortality and renal outcomes in patients with diabetes and
albuminuria: A systematic review and meta-analysis. Kidney Blood
Press Res. 43:768–779. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zheng Z, Lin S and Shi H: A systematic
review and meta-analysis of telmisartan versus valsartan in the
management of essential hypertension. J Clin Hypertens (Greenwich).
12:414–421. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bakris G, Burgess E, Weir M, Davidai G and
Koval S: AMADEO Study Investigators: Telmisartan is more effective
than losartan in reducing proteinuria in patients with diabetic
nephropathy. Kidney Int. 74:364–369. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Naruse M, Koike Y, Kamei N, Sakamoto R,
Yambe Y and Arimitsu M: Effects of azilsartan compared with
telmisartan on insulin resistance in patients with essential
hypertension and type 2 diabetes mellitus: An open-label,
randomized clinical trial. PLoS One. 14(e0214727)2019.PubMed/NCBI View Article : Google Scholar
|
